Václav Šeda

PhD Student

Email:
Phone:	+420 54949 7500, +420 54949 8144
Mobile:	+420 54949 8144
Research group:	Microenvironment of Immune Cells - Marek Mráz
Workplace:	Kamenice 753/5, Brno, 625 00, office E35/281, E35/275

7. Apr. 2021

Press release; The research team, led by associate professor Marek Mraz, described a fundamental mechanism in the biology of chronic lymphocytic…

Publications that are part of the Web of Science database, possibly also other publications chosen by authors.

Sharma, S; Pavlasova, GM; Seda, V; Cerna, KA; Vojackova, E; Filip, D; Ondrisova, L; Sandova, V; Kostalova, L; Zeni, PF; Borsky, M; Oppelt, J; Liskova, K; Kren, L; Janikova, A; Pospisilova, S; Fernandes, SM; Shehata, M; Rassenti, LZ; Jaeger, U; Doubek, M; Davids, MS; Brown, JR; Mayer, J; Kipps, TJ; Mraz, M, 2021: miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors. BLOOD 137(18), p. 2481 - 2494, doi: 10.1182/blood.2020005627

Boudny, M; Zemanova, J; Khirsariya, P; Borsky, M; Verner, J; Cerna, J; Oltova, A; Seda, V; Mraz, M; Jaros, J; Jaskova, Z; Spunarova, M; Brychtova, Y; Soucek, K; Drapela, S; Kasparkova, M; Mayer, J; Paruch, K; Trbusek, M, 2019: Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells. HAEMATOLOGICA 104(12), p. 2443 - 2455, doi: 10.3324/haematol.2018.203430
Cerna, K; Oppelt, J; Musilova, K; Seda, V;Pavlasova, K; Radova, L; Arigoni, M; Calogero, RA; Benes, V; Tbusek, M; Brychtova, Y; Doubek, M; Mayer, J; Pospisilova, S; Mraz, M, 2019: MicroRNA miR-34a downregulates FOXP1 during DNA damage response to limit BCR signalling in chronic lymphocytic leukaemia B cells. LEUKEMIA

Pavlasova, G; Borsky, M; Svobodova, V; Oppelt, J; Cerna, K; Novotna, J; Seda, V; Fojtova, M; Fajkus, J; Brychtova, Y; Doubek, M; Pospisilova, S; Mayer, J; Mraz, M, 2018: Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels. LEUKEMIA 32(9), p. 2028 - 2031, doi: 10.1038/s41375-018-0211-0
Musilova, K; Devan, J; Cerna, K; Seda, V; Pavlasova, G; Sharma, S; Oppelt, J; Pytlik, R; Prochazka, V; Prouzova, Z; Trbusek, M; Zlamalikova, L; Liskova, K; Kruzova, L; Jarosova, M; Mareckova, A; Kornauth, C; Simonitsch-Klupp, I; Schiefer, A; Merkel, O; Mocikova, H; Burda, P; Polakova, K; Kren, L; Mayer, J; Zent, CS; Trneny, M; Evans, A; Janikova, A; Mraz, M, 2018: miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels. BLOOD

Mraz, M; Cerna, K; Oppelt, J; Seda, V; Musilova, K; Pavlasova, G; Mayer, J; Pospisilova, S, 2017: MicroRNA induced by DNA damage response regulates the expression of FOXP1 and therapy response in CLL. LEUKEMIA & LYMPHOMA 58, p. 73 - 74
Pavlasova, G; Borsky, M; Svobodova, V; Musilova, K; Cerna, K; Seda, V; Osickova, J; Brychtova, Y; Doubek, M; Pospisilova, S; Mayer, J; Mraz, M, 2017: BCR SIGNALLING PROFICIENT CHRONIC LYMPHOCYTIC LEUKAEMIA B CELLS ARE PRONE TO RITUXIMAB MEDIATED ELIMINATION IN VIVO. HAEMATOLOGICA 102, p. 412 - 412
Pavlasova, G; Musilova, K; Seda, V; Cerna, K; Vojackova, E; Svobodova, V; Mraz, M, 2017: The identification of combinatorial therapeutic approaches with BCR inhibitors in B cell malignancies. MOLECULAR CANCER THERAPEUTICS 16(10)

Pavlasova, G; Borsky, M; Seda, V; Cerna, K; Osickova, J; Doubek, M; Mayer, J; Calogero, R; Trbusek, M; Pospisilova, S; Davids, MS; Kipps, TJ; Brown, JR; Mraz, M, 2016: Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis. BLOOD 128(12), p. 1609 - 1613, doi: 10.1182/blood-2016-04-709519
Pavlasova, G; Borsky, M; Seda, V; Cerna, K; Osickova, J; Doubek, M; Mayer, J; Calogero, R; Pospisilova, S; Davids, M; Brown, J; Mraz, M, 2016: IBRUTINIB INHIBITS CD20 UP-REGULATION ON CLL B CELLS MEDIATED BY THE CXCR4/SDF-1 AXIS. HAEMATOLOGICA 101, p. 47 - 47